During the current COVID-19 emergency, priority is given to patient care and supporting our individual Trusts and Health Boards. Understandably many questions have arisen about clinical trials and their continuation in the current climate.
Guidance from NIHR can be found HERE.
The BSG suggests that Chief Investigators (CIs) and Principal Investigators (PIs) ensure that risk assessments are undertaken for each study for which they are responsible, to determine if these should be halted or continued. Risk assessments should be documented and discussed with other stakeholders, such as grant authorities or commercial sponsors. If the risk is assessed to be low, (e.g. observational studies or projects that could be undertaken remotely), then these could continue, unless new advice emerges to the contrary.
We will continue to monitor the situation and update accordingly. The BSG is committed to supporting all its members at this difficult time.
We recognise that patients with inflammatory bowel disease, particularly those receiving immunomodulatory drugs, will be understandably worried during the current situation. We are concerned for their well being and have published advice which can be found HERE